Search
Levocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigationalLevocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. … [L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Mixtures: NORAVER ® GFAST CAPSULAS BLANDAS CONTRA LOS SINTOMAS DE LA GRIPA, BREATHEZY - LProducts: L-FALERGI, LEVOCETIRIZIN AL 5MG RXDasabuvir
go.drugbank.com/drugs/DB09183ApprovedIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Dasabuvir as first line therapy … HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852].
Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamidePretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalIt was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.
Streptococcus pneumoniae type 3 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10321ApprovedInvestigationalStreptococcus pneumoniae type 3 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 3 of *Streptococcus pneumoniae*. … It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheEPC2407
go.drugbank.com/drugs/DB05189InvestigationalEPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. … It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized.
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigational[L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line. … It was first approved by the European Commission in January 2018.
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnand 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. … This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors)
Mixtures: Tyrothricin "Provita" comp. - LutschtablettenPropiolactone
go.drugbank.com/drugs/DB09348ApprovedWithdrawnPropiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. … [A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144]
Categories: Compounds used in a research, industrial, or household settingSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. … It is administered as a 1 hour intravenous infusion every 3 weeks.